Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($1.04), $0.44 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $50.52 million versus the consensus estimate of $61.78 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $262.1 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.